301096 百诚医药
已收盘 07-25 15:00:00
资讯
新帖
简况
百诚医药(301096.SZ)预计上半年归母净利润0万元–600万元,同比下降95.53%-100%
智通财经 · 07-15
百诚医药(301096.SZ)预计上半年归母净利润0万元–600万元,同比下降95.53%-100%
7月10日百诚医药涨6.05%,光大信用添益债券A基金重仓该股
证券之星 · 07-10
7月10日百诚医药涨6.05%,光大信用添益债券A基金重仓该股
百诚医药上涨6.32%,报48.12元/股
金融界 · 07-10
百诚医药上涨6.32%,报48.12元/股
【机构调研记录】国寿安保基金调研亚普股份、百诚医药
证券之星 · 07-07
【机构调研记录】国寿安保基金调研亚普股份、百诚医药
【私募调研记录】弘尚资产调研百诚医药
证券之星 · 07-07
【私募调研记录】弘尚资产调研百诚医药
百诚医药:6月30日接受机构调研,财通证券、方正富邦基金等多家机构参与
证券之星 · 07-04
百诚医药:6月30日接受机构调研,财通证券、方正富邦基金等多家机构参与
百诚医药:目前在研的减肥类产品处于早期研究阶段
证券之星 · 07-02
百诚医药:目前在研的减肥类产品处于早期研究阶段
百诚医药(301096)3960万股限售股将于6月20日解禁,占总股本36.25%
证券之星 · 06-20
百诚医药(301096)3960万股限售股将于6月20日解禁,占总股本36.25%
百诚医药:6月16日高管楼金芳增持股份合计7000股
证券之星 · 06-17
百诚医药:6月16日高管楼金芳增持股份合计7000股
百诚医药:6月13日高管楼金芳增持股份合计3000股
证券之星 · 06-16
百诚医药:6月13日高管楼金芳增持股份合计3000股
百诚医药最新公告:控股股东楼金芳拟增持不低于5000万元且不超过1亿元公司股份
证券之星 · 06-12
百诚医药最新公告:控股股东楼金芳拟增持不低于5000万元且不超过1亿元公司股份
百诚医药收盘上涨1.18%,最新市净率1.95,总市值49.84亿元
金融界 · 06-11
百诚医药收盘上涨1.18%,最新市净率1.95,总市值49.84亿元
6月9日百诚医药涨5.36%,光大信用添益债券A基金重仓该股
证券之星 · 06-09
6月9日百诚医药涨5.36%,光大信用添益债券A基金重仓该股
百诚医药(301096)新增【眼科】概念
证券之星 · 06-06
百诚医药(301096)新增【眼科】概念
6月3日百诚医药涨7.06%,光大信用添益债券A基金重仓该股
证券之星 · 06-03
6月3日百诚医药涨7.06%,光大信用添益债券A基金重仓该股
百诚医药:公司全资子公司已布局兽药和宠物药物研发
证券之星 · 05-30
百诚医药:公司全资子公司已布局兽药和宠物药物研发
百诚医药上涨5.63%,报39.78元/股
金融界 · 05-27
百诚医药上涨5.63%,报39.78元/股
百诚医药:杭州百润动保科技有限公司主要开发的兽药及宠物药适应症为驱虫类及慢性病类
证券之星 · 05-26
百诚医药:杭州百润动保科技有限公司主要开发的兽药及宠物药适应症为驱虫类及慢性病类
百诚医药:目前公司暂无资产重组计划,公司致力于保障现有主营业务稳定发展
证券之星 · 05-14
百诚医药:目前公司暂无资产重组计划,公司致力于保障现有主营业务稳定发展
百诚医药:杭州智源生命科技有限公司经营范围包括人工智能应用软件开发技术服务和技术开发等
证券之星 · 05-12
百诚医药:杭州智源生命科技有限公司经营范围包括人工智能应用软件开发技术服务和技术开发等
加载更多
公司概况
公司名称:
杭州百诚医药科技股份有限公司
所属行业:
研究和试验发展
上市日期:
2021-12-20
主营业务:
杭州百诚医药科技股份有限公司的主营业务是为各类制药企业、医药研发投资企业提供:医药技术受托研发服务(CRO业务)、研发技术成果转化服务、定制研发生产服务(CDMO)。公司的主要产品是临床前药学研究、研发技术成果转化、临床服务、CDMO、权益分成及其他。
发行价格:
79.60
{"stockData":{"symbol":"301096","market":"SZ","secType":"STK","nameCN":"百诚医药","latestPrice":48.31,"timestamp":1753427025000,"preClose":48.33,"halted":0,"volume":2379100,"delay":0,"changeRate":-0.0004,"floatShares":109000000,"shares":109000000,"eps":-1.1789,"marketStatus":"已收盘","change":-0.02,"latestTime":"07-25 15:00:00","open":48.35,"high":49.33,"low":48.14,"amount":116000000,"amplitude":0.0246,"askPrice":48.32,"askSize":50,"bidPrice":48.31,"bidSize":3,"shortable":0,"etf":0,"ttmEps":-1.1789,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1753666200000},"marketStatusCode":5,"adr":0,"adjPreClose":48.33,"symbolType":"stock","openAndCloseTimeList":[[1753407000000,1753414200000],[1753419600000,1753426800000]],"highLimit":53.16,"lowLimit":43.5,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":109228284,"isCdr":false,"pbRate":2.07,"roa":"--","roe":"--","epsLYR":-0.49,"committee":-0.060241,"marketValue":5277000000,"turnoverRate":0.0218,"status":1,"floatMarketCap":5266000000},"requestUrl":"/m/hq/s/301096","defaultTab":"news","newsList":[{"id":"2551164824","title":"百诚医药(301096.SZ)预计上半年归母净利润0万元–600万元,同比下降95.53%-100%","url":"https://stock-news.laohu8.com/highlight/detail?id=2551164824","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551164824?lang=zh_cn&edition=full","pubTime":"2025-07-15 19:41","pubTimestamp":1752579690,"startTime":"0","endTime":"0","summary":"智通财经APP讯,百诚医药(301096.SZ)披露2025年半年度业绩预告,公司预计归属于上市公司股东的净利润0万元–600万元,同比下降95.53%-100.00%;扣除非经常性损益后的净亏损900万元–1500万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1318156.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"百诚医药(301096.SZ)预计上半年归母净利润0万元–600万元,同比下降95.53%-100%","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["301096"],"gpt_icon":0},{"id":"2550611779","title":"7月10日百诚医药涨6.05%,光大信用添益债券A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2550611779","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550611779?lang=zh_cn&edition=full","pubTime":"2025-07-10 16:18","pubTimestamp":1752135491,"startTime":"0","endTime":"0","summary":"证券之星消息,7月10日百诚医药涨6.05%,收盘报48.0元,换手率6.32%,成交量6.89万手,成交额3.25亿元。重仓百诚医药的公募基金请见下表:该股最近90天内共有3家机构给出评级,买入评级1家,增持评级2家。根据2025基金Q1季报公募基金重仓股数据,重仓该股的公募基金共2家,其中持有数量最多的公募基金为光大保德信基金的光大信用添益债券A。该公募基金现任基金经理为黄波。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025071000025143.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301096","BK0216"],"gpt_icon":0},{"id":"2550869765","title":"百诚医药上涨6.32%,报48.12元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2550869765","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550869765?lang=zh_cn&edition=full","pubTime":"2025-07-10 13:42","pubTimestamp":1752126175,"startTime":"0","endTime":"0","summary":"7月10日,百诚医药盘中上涨6.32%,截至13:42,报48.12元/股,成交1.57亿元,换手率3.12%,总市值52.56亿元。截至9月30日,百诚医药股东户数1.6万,人均流通股4332股。2024年1月-9月,百诚医药实现营业收入7.21亿元,同比增长1.07%;归属净利润1.42亿元,同比减少29.69%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/07/10134251602701.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK0216","301096"],"gpt_icon":0},{"id":"2549747374","title":"【机构调研记录】国寿安保基金调研亚普股份、百诚医药","url":"https://stock-news.laohu8.com/highlight/detail?id=2549747374","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2549747374?lang=zh_cn&edition=full","pubTime":"2025-07-07 08:01","pubTimestamp":1751846493,"startTime":"0","endTime":"0","summary":"证券之星消息,根据市场公开信息及7月4日披露的机构调研信息,国寿安保基金近期对2家上市公司进行了调研,相关名单如下:1)亚普股份 调研纪要:亚普股份依托全球布局优势和品牌影响力,大力拓展海外业务和市场。国寿安保基金成立于2013年,截至目前,资产管理规模3273.11亿元,排名30/210;资产管理规模1864.32亿元,排名27/210;管理公募基金数176只,排名39/210;旗下公募基金经理38人,排名31/210。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025070700001455.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","BK0264","603013","301096"],"gpt_icon":0},{"id":"2549637474","title":"【私募调研记录】弘尚资产调研百诚医药","url":"https://stock-news.laohu8.com/highlight/detail?id=2549637474","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2549637474?lang=zh_cn&edition=full","pubTime":"2025-07-07 08:01","pubTimestamp":1751846473,"startTime":"0","endTime":"0","summary":"根据市场公开信息及7月4日披露的机构调研信息,知名私募弘尚资产近期对1家上市公司进行了调研,相关名单如下:1)百诚医药 调研纪要:公司积极寻求新的业务增长点,秉承创新药和仿制药研发双线发展思路,布局自主立项的创新药物研发,目前创新药物研发项目众多,广泛布局于肿瘤、自身免疫、神经精神及呼吸道疾病等关键医疗领域。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://fund.stockstar.com/RB2025070700001424.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","301096"],"gpt_icon":0},{"id":"2548398758","title":"百诚医药:6月30日接受机构调研,财通证券、方正富邦基金等多家机构参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2548398758","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2548398758?lang=zh_cn&edition=full","pubTime":"2025-07-04 19:01","pubTimestamp":1751626903,"startTime":"0","endTime":"0","summary":"证券之星消息,2025年7月4日百诚医药发布公告称公司于2025年6月30日接受机构调研,财通证券、方正富邦基金、德邦基金、宝盈基金、运舟资本、国联基金、惠通基金、青骊投资、国寿安保基金、招商基金、弘尚资产、光大保德信、上海开思私募基金、中金公司、摩根基金参与。目前全球抗肿瘤药物以靶向药物为主,占整体市场的 60%以上,免疫治疗药物占比超过化疗药物,市场占比达 23.4%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025070400031639.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0276","301096","BK0216","601108"],"gpt_icon":0},{"id":"2548186406","title":"百诚医药:目前在研的减肥类产品处于早期研究阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2548186406","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2548186406?lang=zh_cn&edition=full","pubTime":"2025-07-02 17:01","pubTimestamp":1751446870,"startTime":"0","endTime":"0","summary":"证券之星消息,百诚医药(301096)07月02日在投资者关系平台上答复投资者关心的问题。投资者提问:有没有减肥药?百诚医药回复:尊敬的投资者您好,公司布局众多前景良好、供应短缺、具有一定技术壁垒的药物品种,目前在研的减肥类产品处于早期研究阶段,感谢您的关注。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025070200026998.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","301096"],"gpt_icon":0},{"id":"2544926361","title":"百诚医药(301096)3960万股限售股将于6月20日解禁,占总股本36.25%","url":"https://stock-news.laohu8.com/highlight/detail?id=2544926361","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2544926361?lang=zh_cn&edition=full","pubTime":"2025-06-20 08:04","pubTimestamp":1750377843,"startTime":"0","endTime":"0","summary":"证券之星消息,根据市场公开信息整理,百诚医药于6月20日将有3960.0万股限售股份解禁,为公司追加承诺限售股份上市流通,占公司总股本36.25%。本次解禁后,公司还有22.11万股限售股份,占总股本0.2%。百诚医药主营业务:公司是一家以技术开发为核心的综合性医药研发企业,主要为各类制药企业、医药研发投资企业提供:医药技术受托研发服务;研发技术成果转化服务;定制研发生产服务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025062000003979.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301096","BK0216"],"gpt_icon":0},{"id":"2544296053","title":"百诚医药:6月16日高管楼金芳增持股份合计7000股","url":"https://stock-news.laohu8.com/highlight/detail?id=2544296053","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2544296053?lang=zh_cn&edition=full","pubTime":"2025-06-17 21:03","pubTimestamp":1750165411,"startTime":"0","endTime":"0","summary":"证券之星消息,根据6月17日市场公开信息、上市公司公告及交易所披露数据整理,百诚医药最新董监高及相关人员股份变动情况:2025年6月16日公司董事,高管楼金芳共增持公司股份7000.0股,占公司总股本为0.0064%。变动期间公司股价上涨0.52%,6月16日当日收盘报44.65元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025061700035173.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","301096"],"gpt_icon":0},{"id":"2543670516","title":"百诚医药:6月13日高管楼金芳增持股份合计3000股","url":"https://stock-news.laohu8.com/highlight/detail?id=2543670516","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2543670516?lang=zh_cn&edition=full","pubTime":"2025-06-16 21:02","pubTimestamp":1750078935,"startTime":"0","endTime":"0","summary":"证券之星消息,根据6月16日市场公开信息、上市公司公告及交易所披露数据整理,百诚医药最新董监高及相关人员股份变动情况:2025年6月13日公司董事,高管楼金芳共增持公司股份3000.0股,占公司总股本为0.0027%。变动期间公司股价下跌3.1%,6月13日当日收盘报44.42元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025061600030859.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301096","BK0216"],"gpt_icon":0},{"id":"2542513920","title":"百诚医药最新公告:控股股东楼金芳拟增持不低于5000万元且不超过1亿元公司股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2542513920","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2542513920?lang=zh_cn&edition=full","pubTime":"2025-06-12 18:40","pubTimestamp":1749724841,"startTime":"0","endTime":"0","summary":"百诚医药(301096.SZ)公告称,公司控股股东楼金芳计划自公告披露之日起6个月内,通过集中竞价交易方式增持公司股份,累计增持金额不低于5000万元且不超过1亿元。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025061200029116.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301096","BK0216"],"gpt_icon":0},{"id":"2542047293","title":"百诚医药收盘上涨1.18%,最新市净率1.95,总市值49.84亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2542047293","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2542047293?lang=zh_cn&edition=full","pubTime":"2025-06-11 17:23","pubTimestamp":1749633787,"startTime":"0","endTime":"0","summary":"6月11日,百诚医药今日收盘45.63元,上涨1.18%,最新市净率1.95,创165天以来新低,总市值49.84亿元。截至2025年一季报,共有8家机构持仓百诚医药,其中基金4家、其他4家,合计持股数1261.81万股,持股市值4.57亿元。公司的主要产品是临床前药学研究、研发技术成果转化、临床服务、CDMO、权益分成及其他。最新一期业绩显示,2025年一季报,公司实现营业收入1.29亿元,同比-40.32%;净利润-26197617.81元,同比-152.59%,销售毛利率41.62%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/06/11172351007698.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["301096","BK0216"],"gpt_icon":0},{"id":"2542809041","title":"6月9日百诚医药涨5.36%,光大信用添益债券A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2542809041","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2542809041?lang=zh_cn&edition=full","pubTime":"2025-06-09 16:31","pubTimestamp":1749457910,"startTime":"0","endTime":"0","summary":"证券之星消息,6月9日百诚医药涨5.36%,收盘报45.61元,换手率15.75%,成交量10.93万手,成交额4.96亿元。重仓百诚医药的公募基金请见下表:该股最近90天内共有5家机构给出评级,买入评级3家,增持评级2家。根据2025基金Q1季报公募基金重仓股数据,重仓该股的公募基金共2家,其中持有数量最多的公募基金为光大保德信基金的光大信用添益债券A。该公募基金现任基金经理为黄波。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025060900020315.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","301096"],"gpt_icon":0},{"id":"2541831175","title":"百诚医药(301096)新增【眼科】概念","url":"https://stock-news.laohu8.com/highlight/detail?id=2541831175","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2541831175?lang=zh_cn&edition=full","pubTime":"2025-06-06 16:25","pubTimestamp":1749198304,"startTime":"0","endTime":"0","summary":"证券之星消息,根据市场公开信息整理,6月6日百诚医药新增概念。百诚医药主营业务:公司是一家以技术开发为核心的综合性医药研发企业,主要为各类制药企业、医药研发投资企业提供:医药技术受托研发服务;研发技术成果转化服务;定制研发生产服务。百诚医药2025年一季报显示,公司主营收入1.29亿元,同比下降40.32%;归母净利润-2619.76万元,同比下降152.59%;扣非净利润-3618.23万元,同比下降174.26%;负债率32.35%,投资收益108.01万元,财务费用344.32万元,毛利率41.62%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025060600024196.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301096","BK0216"],"gpt_icon":0},{"id":"2540472375","title":"6月3日百诚医药涨7.06%,光大信用添益债券A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2540472375","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2540472375?lang=zh_cn&edition=full","pubTime":"2025-06-03 16:05","pubTimestamp":1748937910,"startTime":"0","endTime":"0","summary":"证券之星消息,6月3日百诚医药涨7.06%创60日新高,收盘报42.93元,换手率17.54%,成交量12.18万手,成交额5.04亿元。重仓百诚医药的公募基金请见下表:该股最近90天内共有5家机构给出评级,买入评级3家,增持评级2家。根据2025基金Q1季报公募基金重仓股数据,重仓该股的公募基金共2家,其中持有数量最多的公募基金为光大保德信基金的光大信用添益债券A。该公募基金现任基金经理为黄波。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025060300018844.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301096","BK0216"],"gpt_icon":0},{"id":"2539231862","title":"百诚医药:公司全资子公司已布局兽药和宠物药物研发","url":"https://stock-news.laohu8.com/highlight/detail?id=2539231862","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2539231862?lang=zh_cn&edition=full","pubTime":"2025-05-30 17:54","pubTimestamp":1748598844,"startTime":"0","endTime":"0","summary":"证券之星消息,百诚医药(301096)05月30日在投资者关系平台上答复投资者关心的问题。投资者提问:请问贵公司及子公司或与之相关的参股公司有没有研发兽药或者宠物用药?是否上市运营?百诚医药回复:尊敬的投资者您好,公司全资子公司杭州百润动保科技有限公司已布局兽药和宠物药物研发,适应症为驱虫类及慢性病类,感谢您的关注。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025053000028971.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301096","BK0216"],"gpt_icon":0},{"id":"2538480177","title":"百诚医药上涨5.63%,报39.78元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2538480177","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2538480177?lang=zh_cn&edition=full","pubTime":"2025-05-27 10:40","pubTimestamp":1748313604,"startTime":"0","endTime":"0","summary":"5月27日,百诚医药盘中上涨5.63%,截至10:40,报39.78元/股,成交1.76亿元,换手率6.52%,总市值43.45亿元。截至9月30日,百诚医药股东户数1.6万,人均流通股4332股。2024年1月-9月,百诚医药实现营业收入7.21亿元,同比增长1.07%;归属净利润1.42亿元,同比减少29.69%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/05/27104050672562.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["301096","BK0216"],"gpt_icon":0},{"id":"2538214178","title":"百诚医药:杭州百润动保科技有限公司主要开发的兽药及宠物药适应症为驱虫类及慢性病类","url":"https://stock-news.laohu8.com/highlight/detail?id=2538214178","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2538214178?lang=zh_cn&edition=full","pubTime":"2025-05-26 16:09","pubTimestamp":1748246966,"startTime":"0","endTime":"0","summary":"证券之星消息,百诚医药(301096)05月26日在投资者关系平台上答复投资者关心的问题。投资者提问:请问百诚医药子公司杭州百润动保科技有限公司开发了哪些兽药及宠物药?是否有营收?百诚医药回复:尊敬的投资者您好,杭州百润动保科技有限公司主要开发的兽药及宠物药适应症为驱虫类及慢性病类。感谢您的关注。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025052600019088.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","301096"],"gpt_icon":0},{"id":"2535042377","title":"百诚医药:目前公司暂无资产重组计划,公司致力于保障现有主营业务稳定发展","url":"https://stock-news.laohu8.com/highlight/detail?id=2535042377","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2535042377?lang=zh_cn&edition=full","pubTime":"2025-05-14 18:54","pubTimestamp":1747220051,"startTime":"0","endTime":"0","summary":"证券之星消息,百诚医药(301096)05月14日在投资者关系平台上答复投资者关心的问题。投资者提问:尊敬的董秘,您好!请问贵公司最近有没有资产重组计划在进行,公司效益前景如何?百诚医药回复:尊敬的投资者您好,目前公司暂无资产重组计划,公司致力于保障现有主营业务稳定发展,感谢您的关注。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025051400029848.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301096","BK0216"],"gpt_icon":0},{"id":"2534220266","title":"百诚医药:杭州智源生命科技有限公司经营范围包括人工智能应用软件开发技术服务和技术开发等","url":"https://stock-news.laohu8.com/highlight/detail?id=2534220266","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2534220266?lang=zh_cn&edition=full","pubTime":"2025-05-12 20:54","pubTimestamp":1747054474,"startTime":"0","endTime":"0","summary":"证券之星消息,百诚医药(301096)05月12日在投资者关系平台上答复投资者关心的问题。投资者提问:请问公司新参股的杭州智源生命科技有限公司是准备从事哪些业务?百诚医药为何投资?百诚医药回复:尊敬的投资者您好,杭州智源生命科技有限公司经营范围包括人工智能应用软件开发,技术服务和技术开发等,感谢您的关注。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025051200032029.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","161631","301096"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1753435619130,"stockEarnings":[{"period":"1week","weight":-0.0254},{"period":"1month","weight":0.0752},{"period":"3month","weight":0.4645},{"period":"6month","weight":0.4119},{"period":"1year","weight":0.0516},{"period":"ytd","weight":0.2739}],"compareEarnings":[{"period":"1week","weight":0.0253},{"period":"1month","weight":0.0541},{"period":"3month","weight":0.0943},{"period":"6month","weight":0.1086},{"period":"1year","weight":0.2425},{"period":"ytd","weight":0.0758}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"杭州百诚医药科技股份有限公司","boardCode":"AI0073","boardName":"研究和试验发展","stockholders":"16188人(较上一季度减少5.82%)","perCapita":"6733股","listingDate":"2021-12-20","address":"浙江省杭州市临平区临平街道绿洲路159号","registeredCapital":"10922万元","survey":" 杭州百诚医药科技股份有限公司的主营业务是为各类制药企业、医药研发投资企业提供:医药技术受托研发服务(CRO业务)、研发技术成果转化服务、定制研发生产服务(CDMO)。公司的主要产品是临床前药学研究、研发技术成果转化、临床服务、CDMO、权益分成及其他。","listedPrice":79.6},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.34.4","shortVersion":"4.34.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"百诚医药(301096)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供百诚医药(301096)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"百诚医药,301096,百诚医药股票,百诚医药股票老虎,百诚医药股票老虎国际,百诚医药行情,百诚医药股票行情,百诚医药股价,百诚医药股市,百诚医药股票价格,百诚医药股票交易,百诚医药股票购买,百诚医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"百诚医药(301096)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供百诚医药(301096)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}